Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice

JoEllyn M McMillan, Denise A. Cobb, Zhiyi Lin, Mary G. Banoub, Raghubendra S. Dagur, Amanda A. Branch Woods, Weimin Wang, Edward Makarov, Ted Kocher, Poonam S. Joshi, Rolen M. Quadros, Donald W. Harms, Samuel Monroe Cohen, Howard Eliot Gendelman, Channabasavaiah B Gurumurthy, Santhi Gorantla, Larisa Y Poluektova

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Antiretroviral drug (ARV) metabolism is linked largely to hepatic cytochrome P450 activity. One ARV drug class known to be metabolized by intestinal and hepatic CYP3A are the protease inhibitors (PIs). Plasma drug concentrations are boosted by CYP3A inhibitors such as cobisistat and ritonavir (RTV). Studies of such drug-drug interactions are limited since the enzyme pathways are human specific. While immune-deficient mice reconstituted with human cells are an excellent model to study ARVs during human immunodeficiency virus type 1 (HIV-1) infection, they cannot reflect human drug metabolism. Thus, we created a mouse strain with the human pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 genes on a NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac background (hCYP3A-NOG) and used them to evaluate the impact of human CYP3A metabolism on ARV pharmacokinetics. In proof-of-concept studies we used nanoformulated atazanavir (nanoATV) with or without RTV. NOG and hCYP3A-NOG mice were treated weekly with 50 mg/kg nanoATV alone or boosted with nanoformulated ritonavir (nanoATV/r). Plasma was collected weekly and liver was collected at 28 days post-treatment. Plasma and liver atazanavir (ATV) concentrations in nanoATV/r-treated hCYP3A-NOG mice were 2- to 4-fold higher than in replicate NOG mice. RTV enhanced plasma and liver ATV concentrations 3-fold in hCYP3A-NOG mice and 1.7-fold in NOG mice. The results indicate that human CYP3A-mediated drug metabolism is reduced compared with mouse and that RTV differentially affects human gene activity. These differences can affect responses to PIs in humanized mouse models of HIV-1 infection. Importantly, hCYP3A-NOG mice reconstituted with human immune cells can be used for bench-to-bedside translation.

Original languageEnglish (US)
Pages (from-to)272-280
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume365
Issue number2
DOIs
StatePublished - May 1 2018

Fingerprint

Cytochrome P-450 CYP3A
Ritonavir
Pharmaceutical Preparations
Liver
Virus Diseases
Protease Inhibitors
HIV-1
Drug Interactions
Human Activities
Cytochrome P-450 Enzyme System
Genes
Pharmacokinetics
Atazanavir Sulfate

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice. / McMillan, JoEllyn M; Cobb, Denise A.; Lin, Zhiyi; Banoub, Mary G.; Dagur, Raghubendra S.; Branch Woods, Amanda A.; Wang, Weimin; Makarov, Edward; Kocher, Ted; Joshi, Poonam S.; Quadros, Rolen M.; Harms, Donald W.; Cohen, Samuel Monroe; Gendelman, Howard Eliot; Gurumurthy, Channabasavaiah B; Gorantla, Santhi; Poluektova, Larisa Y.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 365, No. 2, 01.05.2018, p. 272-280.

Research output: Contribution to journalArticle

McMillan, JM, Cobb, DA, Lin, Z, Banoub, MG, Dagur, RS, Branch Woods, AA, Wang, W, Makarov, E, Kocher, T, Joshi, PS, Quadros, RM, Harms, DW, Cohen, SM, Gendelman, HE, Gurumurthy, CB, Gorantla, S & Poluektova, LY 2018, 'Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice', Journal of Pharmacology and Experimental Therapeutics, vol. 365, no. 2, pp. 272-280. https://doi.org/10.1124/jpet.117.247288
McMillan, JoEllyn M ; Cobb, Denise A. ; Lin, Zhiyi ; Banoub, Mary G. ; Dagur, Raghubendra S. ; Branch Woods, Amanda A. ; Wang, Weimin ; Makarov, Edward ; Kocher, Ted ; Joshi, Poonam S. ; Quadros, Rolen M. ; Harms, Donald W. ; Cohen, Samuel Monroe ; Gendelman, Howard Eliot ; Gurumurthy, Channabasavaiah B ; Gorantla, Santhi ; Poluektova, Larisa Y. / Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice. In: Journal of Pharmacology and Experimental Therapeutics. 2018 ; Vol. 365, No. 2. pp. 272-280.
@article{36d23f75969e4921a3bfd83bf888c2d1,
title = "Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice",
abstract = "Antiretroviral drug (ARV) metabolism is linked largely to hepatic cytochrome P450 activity. One ARV drug class known to be metabolized by intestinal and hepatic CYP3A are the protease inhibitors (PIs). Plasma drug concentrations are boosted by CYP3A inhibitors such as cobisistat and ritonavir (RTV). Studies of such drug-drug interactions are limited since the enzyme pathways are human specific. While immune-deficient mice reconstituted with human cells are an excellent model to study ARVs during human immunodeficiency virus type 1 (HIV-1) infection, they cannot reflect human drug metabolism. Thus, we created a mouse strain with the human pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 genes on a NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac background (hCYP3A-NOG) and used them to evaluate the impact of human CYP3A metabolism on ARV pharmacokinetics. In proof-of-concept studies we used nanoformulated atazanavir (nanoATV) with or without RTV. NOG and hCYP3A-NOG mice were treated weekly with 50 mg/kg nanoATV alone or boosted with nanoformulated ritonavir (nanoATV/r). Plasma was collected weekly and liver was collected at 28 days post-treatment. Plasma and liver atazanavir (ATV) concentrations in nanoATV/r-treated hCYP3A-NOG mice were 2- to 4-fold higher than in replicate NOG mice. RTV enhanced plasma and liver ATV concentrations 3-fold in hCYP3A-NOG mice and 1.7-fold in NOG mice. The results indicate that human CYP3A-mediated drug metabolism is reduced compared with mouse and that RTV differentially affects human gene activity. These differences can affect responses to PIs in humanized mouse models of HIV-1 infection. Importantly, hCYP3A-NOG mice reconstituted with human immune cells can be used for bench-to-bedside translation.",
author = "McMillan, {JoEllyn M} and Cobb, {Denise A.} and Zhiyi Lin and Banoub, {Mary G.} and Dagur, {Raghubendra S.} and {Branch Woods}, {Amanda A.} and Weimin Wang and Edward Makarov and Ted Kocher and Joshi, {Poonam S.} and Quadros, {Rolen M.} and Harms, {Donald W.} and Cohen, {Samuel Monroe} and Gendelman, {Howard Eliot} and Gurumurthy, {Channabasavaiah B} and Santhi Gorantla and Poluektova, {Larisa Y}",
year = "2018",
month = "5",
day = "1",
doi = "10.1124/jpet.117.247288",
language = "English (US)",
volume = "365",
pages = "272--280",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice

AU - McMillan, JoEllyn M

AU - Cobb, Denise A.

AU - Lin, Zhiyi

AU - Banoub, Mary G.

AU - Dagur, Raghubendra S.

AU - Branch Woods, Amanda A.

AU - Wang, Weimin

AU - Makarov, Edward

AU - Kocher, Ted

AU - Joshi, Poonam S.

AU - Quadros, Rolen M.

AU - Harms, Donald W.

AU - Cohen, Samuel Monroe

AU - Gendelman, Howard Eliot

AU - Gurumurthy, Channabasavaiah B

AU - Gorantla, Santhi

AU - Poluektova, Larisa Y

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Antiretroviral drug (ARV) metabolism is linked largely to hepatic cytochrome P450 activity. One ARV drug class known to be metabolized by intestinal and hepatic CYP3A are the protease inhibitors (PIs). Plasma drug concentrations are boosted by CYP3A inhibitors such as cobisistat and ritonavir (RTV). Studies of such drug-drug interactions are limited since the enzyme pathways are human specific. While immune-deficient mice reconstituted with human cells are an excellent model to study ARVs during human immunodeficiency virus type 1 (HIV-1) infection, they cannot reflect human drug metabolism. Thus, we created a mouse strain with the human pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 genes on a NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac background (hCYP3A-NOG) and used them to evaluate the impact of human CYP3A metabolism on ARV pharmacokinetics. In proof-of-concept studies we used nanoformulated atazanavir (nanoATV) with or without RTV. NOG and hCYP3A-NOG mice were treated weekly with 50 mg/kg nanoATV alone or boosted with nanoformulated ritonavir (nanoATV/r). Plasma was collected weekly and liver was collected at 28 days post-treatment. Plasma and liver atazanavir (ATV) concentrations in nanoATV/r-treated hCYP3A-NOG mice were 2- to 4-fold higher than in replicate NOG mice. RTV enhanced plasma and liver ATV concentrations 3-fold in hCYP3A-NOG mice and 1.7-fold in NOG mice. The results indicate that human CYP3A-mediated drug metabolism is reduced compared with mouse and that RTV differentially affects human gene activity. These differences can affect responses to PIs in humanized mouse models of HIV-1 infection. Importantly, hCYP3A-NOG mice reconstituted with human immune cells can be used for bench-to-bedside translation.

AB - Antiretroviral drug (ARV) metabolism is linked largely to hepatic cytochrome P450 activity. One ARV drug class known to be metabolized by intestinal and hepatic CYP3A are the protease inhibitors (PIs). Plasma drug concentrations are boosted by CYP3A inhibitors such as cobisistat and ritonavir (RTV). Studies of such drug-drug interactions are limited since the enzyme pathways are human specific. While immune-deficient mice reconstituted with human cells are an excellent model to study ARVs during human immunodeficiency virus type 1 (HIV-1) infection, they cannot reflect human drug metabolism. Thus, we created a mouse strain with the human pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 genes on a NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac background (hCYP3A-NOG) and used them to evaluate the impact of human CYP3A metabolism on ARV pharmacokinetics. In proof-of-concept studies we used nanoformulated atazanavir (nanoATV) with or without RTV. NOG and hCYP3A-NOG mice were treated weekly with 50 mg/kg nanoATV alone or boosted with nanoformulated ritonavir (nanoATV/r). Plasma was collected weekly and liver was collected at 28 days post-treatment. Plasma and liver atazanavir (ATV) concentrations in nanoATV/r-treated hCYP3A-NOG mice were 2- to 4-fold higher than in replicate NOG mice. RTV enhanced plasma and liver ATV concentrations 3-fold in hCYP3A-NOG mice and 1.7-fold in NOG mice. The results indicate that human CYP3A-mediated drug metabolism is reduced compared with mouse and that RTV differentially affects human gene activity. These differences can affect responses to PIs in humanized mouse models of HIV-1 infection. Importantly, hCYP3A-NOG mice reconstituted with human immune cells can be used for bench-to-bedside translation.

UR - http://www.scopus.com/inward/record.url?scp=85045012848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045012848&partnerID=8YFLogxK

U2 - 10.1124/jpet.117.247288

DO - 10.1124/jpet.117.247288

M3 - Article

VL - 365

SP - 272

EP - 280

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -